UPDATE 1-US panel backs Biogen, Elan MS drug for Crohn's

(Reuters) - The U.S. Food and Drug Administration usually follows
advisory panel recommendations. A final decision is expected by
mid-October.




Tysabri sales were suspended in 2005 because of a rare but
potentially fatal brain infection known as progressive
multifocal leukoencephalopathy, or PML. Two of three patients
who developed PML died.


Read more at Reuters.com Government Filings News